SOZO vs Aima Diagnostics

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

SOZO

by ImpediMed Limited

Aima Diagnostics

by Aima Diagnostics

AI Verdict

SOZO is a non-invasive bioimpedance spectroscopy device focused on early detection and management of lymphedema and body composition analysis. Aima Diagnostics, on the other hand, provides AI-powered interpretation of blood test results for early disease detection and personalized health insights. While both offer clinical decision support and diagnostics, SOZO is a physical device measuring fluid and tissue composition, whereas Aima Diagnostics is a software solution analyzing existing blood test data.

Choose SOZO if…

Choose SOZO by ImpediMed if your primary need is the early detection and ongoing management of lymphedema, particularly in oncology and general surgery settings. Its non-invasive bioimpedance spectroscopy (BIS) technology provides rapid L-Dex scores and detailed body composition analysis, enabling proactive intervention and monitoring of fluid status. The device is also well-suited for tracking fluid buildup in at-risk limbs and can integrate results with patient medical records.

View SOZO →

Choose Aima Diagnostics if…

Choose Aima Diagnostics if you require AI-powered, personalized interpretation of blood test results for early disease detection and informed clinical decisions across a broad range of specialties. This tool excels at analyzing complex biomarker relationships, identifying subtle irregularities, and providing comprehensive, contextualized reports that go beyond standard reference ranges. It is particularly beneficial for laboratories and clinics seeking to enhance diagnostic accuracy, reduce human error, and support physicians with advanced analytical insights.

View Aima Diagnostics →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	SOZO	Aima Diagnostics
Deployment	Cloud	Cloud-based, API integration, or selective AI testing.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Unknown
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

SOZO

SOZO by ImpediMed appears to have a highly intuitive and streamlined user experience. It offers a rapid, non-invasive 30-second scan with an on-screen guide, clear reporting with visual summaries, and trend tracking, designed for clinical workflow and ease of use for clinicians. Aima Diagnostics focuses on providing detailed reports and insights, which, while valuable, may require more active engagement and interpretation from the user compared to SOZO's quick scan and immediate, clear results.

Clinical Value

SOZO

SOZO by ImpediMed has strong clinical validation, including the PREVENT trial which demonstrated a 92% reduction in progression to chronic lymphedema with BIS technology and early intervention. It is also the only FDA-cleared BIS technology for breast cancer-related lymphedema. Aima Diagnostics emphasizes its AI's ability to detect subtle deviations and provide personalized insights for early disease detection, and states its algorithms are trained on millions of laboratory records and provide precise, structured interpretations. However, specific large-scale clinical trial outcomes for Aima Diagnostics' core offering are not as prominently detailed in the provided information as they are for SOZO.

Pricing & Value

Tie

SOZO by ImpediMed operates on a SaaS model, with software upgrades available at no additional cost to users. However, specific pricing for the device itself is not publicly available. Aima Diagnostics offers different plans for clinics and laboratories, including API integration or selective AI testing, but their pricing is also not publicly available. Without transparent pricing for either tool, it is difficult to definitively assess which offers better value.

Enterprise Readiness

SOZO

SOZO by ImpediMed is designed for a target size ranging from solo practices to large health systems and has over 1,100 devices in use globally, indicating significant adoption and scalability. It also offers cloud-based data management and the ability to integrate patient data with EHRs for auto-documentation. Aima Diagnostics targets laboratories and clinics and offers cloud-based deployment, API integration, and compliance with GDPR and HIPAA, but its customer count or widespread enterprise adoption is not as clearly stated.

Innovation

SOZO

SOZO by ImpediMed utilizes proprietary Bioimpedance Spectroscopy (BIS) technology, which is FDA-cleared and has been recognized with innovation awards. It offers a unique, non-invasive method for early lymphedema detection and comprehensive body composition analysis. Aima Diagnostics leverages AI for personalized interpretation of blood tests, analyzing biomarkers within individual contexts for early disease detection, which is also innovative. However, SOZO's established and recognized proprietary hardware technology gives it a slight edge in this dimension.

Support & Docs

SOZO

ImpediMed provides comprehensive support for SOZO, including an online support center with FAQs, IFU documents, help videos, and direct customer and technical support via phone and email across multiple regions. Aima Diagnostics mentions priority email support for its basic plan and dedicated support with an SLA for its Pro plan, along with a WhatsApp text-only customer support line, but the breadth of its documentation and support resources appears less extensive than SOZO's.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	SOZO	Aima Diagnostics
Name	SOZO	Aima Diagnostics
Description	Non-invasive bioimpedance spectroscopy (BIS) device for early detection and management of lymphedema, providing L-Dex scores and body composition analysis.	AI-powered personalized interpretation of blood test results for individuals, physicians, and clinics, analyzing biomarkers within individual contexts for early disease detection and informed decisions.
Company	ImpediMed Limited	Aima Diagnostics
Key Technology	Bioimpedance Spectroscopy (BIS) technology	AI-powered biomarker analysis, Advanced liquid biopsy technology
Primary Use Case	Lymphedema detection and management, body composition analysis	Personalized interpretation of blood tests for early disease detection and informed decisions
Scan/Analysis Time	Rapid, non-invasive 30-second scan	Processing speed up to 50 times faster than traditional laboratory testing
Target User Size	Solo to large health systems	Laboratories and clinics aiming for maximum accuracy and compliance with quality standards, private clinics, telemedicine services, and mobile diagnostic centers.

Videos

Demos, reviews, and walkthroughs featuring SOZO and Aima Diagnostics.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

SOZO is designed for seamless integration into routine intake and follow-up visits, allowing for automatic transfer of measurement data directly into EHR systems, which can save time and improve workflow efficiency. Aima Diagnostics also emphasizes seamless integration into a clinic's workflow, offering API integration or selective AI testing to enhance efficiency without requiring major changes.

What is the accuracy and sensitivity of each tool for its intended purpose?

SOZO's L-Dex score for lymphedema assessment has an area under the curve (AUC) of 0.95 for unilateral assessment and 0.80 for bilateral assessment, indicating high accuracy. Aima Diagnostics uses advanced machine learning algorithms trained on millions of laboratory records to analyze blood test results with exceptional accuracy, aiming to detect hidden abnormalities and provide personalized insights. Personalized approaches in blood diagnostics, like Aima's, can increase accuracy by 10-30%, with potential improvements up to 40%.

Which medical specialties are these tools best suited for?

SOZO is primarily designed for the early detection and ongoing management of lymphedema, making it highly suitable for specialties such as General Surgery and Oncology, particularly for cancer survivorship programs. Aima Diagnostics is geared towards personalized interpretation of blood test results across a broader range of specialties including Cardiology, Endocrinology, Family Medicine, Gastroenterology, Internal Medicine, and Oncology, focusing on early disease detection and informed decisions.

What is the learning curve for physicians and their staff to effectively use these tools?

SOZO is described as fast, intuitive, and repeatable, designed to fit seamlessly into routine intake and follow-up visits, suggesting a relatively low learning curve. Aima Diagnostics aims to enhance efficiency without requiring major changes to workflow, implying that its integration and use are straightforward for clinics.

What security measures beyond HIPAA are in place to protect patient data?

SOZO is HITRUST certified, and all data is encrypted in motion and at rest, with no patient data stored on the device itself. It also features detailed user logs for audit trails, multi-factor authentication (MFA), and Single Sign-On (SSO) support. Aima Diagnostics ensures end-to-end encryption of patient data during all processing stages, uses anonymized data for analysis, and is compliant with GDPR. They are also developing an optional blockchain recording feature for immutable audit trails of interpretations.

Are there audit trail features available to track system usage and data access?

SOZO provides detailed user logs for audit trails, which can be exported directly from MySOZO. These logs include the identity of users who have viewed pages or information, retrieved data, and their login/logout times. Aima Diagnostics' standards for AI-based blood data processing require all access and changes to be logged with immutable audit trails, retained for a minimum of 10 years.

How do these tools support multi-site rollouts for larger health systems?

SOZO's cloud-based infrastructure and EHR integration capabilities are ideal for larger corporate clients with multiple sites, supporting coordinated care across specialties and enabling remote updates and access to patient trends and analytics. Aima Diagnostics' cloud-based deployment, API integration, and focus on laboratories and clinics aiming for maximum accuracy and compliance suggest it can support multi-site rollouts by providing a consistent and scalable solution for blood test interpretation.